thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011;34:145–150.
19Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233–240.
20Stratton IM, Adler AI, Neil HA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.
21Zoungas S, Chalmers J, Ninomiya T, et al: Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012;55:636–643.
22Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234.
23Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I: Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009;26:142–148.
24Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ: Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med 2016;31:387–393.
25Peters SA, Huxley RR, Woodward M: Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014;57:1542–1551.
26Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W: Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care 2008;31:1389–1391.
27Ryden L, Grant PJ, Anker SD, et al: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035–3087.
28American Diabetes Association: 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care 2018;41(suppl 1):S86–S104.
29National Institute for Health and Care Excellence (NICE). Clinical Guideline 181: Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification. London, NICE, 2014.
30Kannel WB, McGee D, Gordon T: A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976;38:46–51.
31van Dieren S, Beulens JW, Kengne AP, et al: Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012;98:360–369.
32Woodward M, Tunstall-Pedoe H, Peters SA: Graphics and statistics for cardiology: clinical prediction rules. Heart 2017;103:538–545.
33Hajifathalian K, Ueda P, Lu Y, et al: A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol 2015;3:339–355.
34Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD: Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;3:CD006887.
35Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ: Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ 2000;320:686–690.
36Hall LM, Jung RT, Leese GP: Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ 2003;326:251–252.
37International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels, International Diabetes Federation, 2012.
38British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association: JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 5):v1–v52.
39World Health Organisation. Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk. Geneva, World Health Organisation, 2007.
40National Vascular Disease Prevention Alliance. Guidelines for the Management of Absolute Cardiovascular Disease Risk. Canberra, National Vascular Disease Prevention Alliance, 2012.
41Backholer K, Hirakawa Y, Tonkin A, et al: Development of an Australian cardiovascular disease mortality risk score using multiple imputation and recalibration from national statistics. BMC Cardiovasc Disord 2017;17:17.
42Hippisley-Cox J, Coupland C, Brindle P: Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099.
43Bachmann KN, Wang TJ: Biomarkers of cardiovascular disease: contributions to risk prediction in individuals with diabetes. Diabetologia 2018;61:987–995.
44Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O: Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48:156–163.
45Hendriks SH, van Dijk PR, van Hateren KJ, et al: High-sensitive troponin T is associated with all-cause and cardiovascular mortality in stable outpatients with type 2 diabetes (ZODIAC-37). Am Heart J 2016;174:43–50.
46Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T: High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care
